Novel Innovations in Health Care
The Good Pharmaceutical Team
Larry Good, MD, F.A.C.G, CEO
Dr. Larry Good has been a practicing gastroenterologist since 1978. After graduating Magna Cum Laude from Colgate University in 1969, he received his M.D. with Alpha Omega Alpha status from the Medical University of South Carolina 1973.
Dr. Good performed his residency from 1973-1976 and was named Chief Medical Resident in 1976. He then completed a fellowship in gastroenterology from 1976-1978 at the University of Pennsylvania.
​
Previously, Dr. Good served as the Director of Liver Diseases at Nassau County Medical Center, Chief of the Division of Gastroenterology at South Nassau Communities Hospital and Chief Medical Office at Ritter Pharmaceuticals in Los Angeles, California.
During his time at Ritter Pharmaceuticals, Dr. Good expanded his research to include the intestinal microbiome. His current clinical research activities involve microbiome, inflammatory bowel disease, irritable bowel syndrome and the application of orally administered gamma globulin to patients with acute and chronic gastrointestinal disorders.
in 2014, Dr. Good founded Good Pharmaceutical Development Co., LLC. He is the company's CEO and head of development of topical products for acute and chronic pain.
​
Dr. Good is a Senior Research Fellow and a member of the Steering Committee of the Lambert Center for Hemp and Marijuana Research at Thomas Jefferson University. He has given hundreds of lectures in his field, authored numerous papers and abstracts and presented at multiple national and international conferences.
​
Dr. Good is also an assistant clinical professor at SUNY Stony Brook.
Michael Ferguson, BS
​
Michael Ferguson Is the owner and CEO of TAB Clinical, a specialty CRO located in Cary, North Carolina.
He holds degrees in Business and Psychology and has over 30 years of executive management experience of several global companies including SmithKline Beecham, Baxter, Searle and American Sterilizer Company (now Steris).
Ferguson's accomplishments include the pharma and semi-conductor markets to novel contamination control products, manufacturing techniques and static control packaging. He has also been involved in managing the reorganization of companies for IPO purposes, startup of new divisions, acquisitions of both domestic and international companies and acquisition of TAB Clinical.
Ferguson purchased TAB Clinical Trials in 2004 and has focused on growing the specialty CRO into a global mid-size CRO with a portfolio of services including medical writing, clinical trial management, data management, statistics and pharmacovigilance .
He also co-founded Sterilization Technology Group in 2005 to help explore novel techniques to control biological contamination within the pharmaceutical manufacturing industry. He has been involved with product launch, pharma services, equipment validations as well as clinical trials for medical devices, drugs and medical foods while working with the FDA and all applicable guidelines.
David Bensol, R. Ph
David Bensol, R. Ph., began his career in the healthcare industry as a Registered Pharmacist and is licensed by the State of New York.
Bensol is a Management Consultant and has been the President of Bensol Holdings Corp., a multi-faceted private investment company since 1978.
He is an accomplished entrepreneur with over 30 years of experience in the healthcare industry. Bensol previously served as a Strategic Advisor at Stat Health Services Inc., as the Chief Executive Officer and Chairman of Arcadia Resources Inc. (formerly, Critical Home Care Inc.) and as its Executive Vice President.
​
Bensol serves on the Board of Directors of various private and publicly traded corporations. Current investments consist of Bensol Realty Corp., Nations Prescription Discount Card, LLC, New York Pharmacy Network, LLC, and Good Pharmaceutical Development Company, LLC.
